Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized therapy for metastatic pancreatic adenocarcinoma (AVATAR)
NCT02795650Phase 2Unknown
- Sponsor
- Hospital Universitario de Fuenlabrada
- Start
- May 2016
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (2 arms), sponsored by Hospital Universitario de Fuenlabrada. Primary endpoint: 1-year overall survival. Status: unknown.
02
Conditions
pancreatic adenocarcinoma
Beyond the preview
Go deeper on NCT02795650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795650.